IP217 Does Metformin Have an Effect on Stent Patency Rates?
Today, metformin is considered to be the first-choice drug and is considered the gold standard for most people with type 2 diabetes. Metformin is the most commonly used diabetic medication used worldwide. Metformin use in patients with congestive heart failure, moderate chronic kidney disease, or chronic liver disease with hepatic impairment is associated with improvements in mortality. Research has shown that metformin also has a protective effect on endothelium by decreasing endothelial vascular reactivity.
Source: Journal of Vascular Surgery - Category: Surgery Authors: Pavel Kibrik, Tereza Izakovich, Jesse Victory, Matthew A. Goldstein, Christina M. Monteleone, Ahmad Alsheekh, Anil Hingorani, Enrico Ascher Tags: IP: Interactive Poster Session Source Type: research
More News: Cardiology | Chronic Kidney Disease | Congestive Heart Failure | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Heart Failure | Liver | Liver Disease | Metformin | Urology & Nephrology